Poplar Therapeutics

Executive Summary

Poplar Therapeutics is a preclinical-stage gene therapy company founded in 2022, focused on developing one-time transformative treatments for severe neurological and rare diseases. The company leverages advanced capsid engineering and vector design to create targeted and potent therapies, aiming to address conditions with high unmet need where conventional treatments are inadequate. Poplar has raised $50 million to date, reflecting investor confidence in its platform technology and pipeline. Its lead programs target central nervous system disorders, leveraging proprietary delivery technologies to overcome blood-brain barrier challenges and achieve durable expression. The company's approach has the potential to provide lifelong benefits for patients, though it remains in early stages with no clinical data yet.

Upcoming Catalysts (preview)

• H1 2027Lead Program IND Filing40% success
• H2 2026Preclinical Proof-of-Concept Data Presentation60% success
• H2 2026Series B Financing Announcement70% success